
    
      The advancements in the treatment of mental health patients with DMS will enable healthcare
      professionals to assess suboptimal adherence and make more informed treatment decisions. In
      addition to these improvements, it will also provide a platform for engagement between
      participants, healthcare professionals, and caregivers/support persons.

      Participants who entered the trial were treated with one of the oral atypical antipsychotics
      defined in the trial (aripiprazole, olanzapine, quetiapine, or risperidone [though no
      participant took risperidone in this trial]). The treatment medication decision was
      determined by the healthcare professionals.
    
  